Molecular structure of salbutamol
Find information on thousands of medical conditions and prescription drugs.

Volmax

Salbutamol (INN) or albuterol (USAN) is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and COPD. It is marketed by the Allen & Hanbury's respiratory division of GlaxoSmithKline under the trade name Ventolin. The name Albuterol comes from Salbutamol aerosol. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

Salbutamol sulfate is usually given by the inhaled route for direct effect on bronchial smooth muscle. This is usually achieved through a metered-dose inhaler (MDI) or nebuliser; but other delivery devices marketed for salbutamol sulfate include the Rotahaler, Diskhaler, and Autohaler. Salbutamol can also be given orally (Volmax®) or intravenously.

Ventolin became available in the United Kingdom in 1969 and in the United States in 1980.

Clinical use

Salbutamol is specifically indicated in the following conditions:

  • acute asthma
  • symptom relief during maintenance therapy of asthma and other conditions with reversible airways obstruction (including COPD)
  • protection against exercise-induced asthma
  • certain conditions involving hyperkalemia

Salbutamol has many bad side effects, including shakiness and tremors.

As a β2-agonist, salbutamol also finds use in obstetrics. Intravenous salbutamol can be used as a tocolytic to relax the uterine smooth muscle to delay premature labour. Whilst preferred over agents such as atosiban and ritodrine, its role has largely been replaced by the calcium-channel blocker nifedipine which is more effective, better tolerated and orally administered. (Rossi, 2004)

Mode of action

As with other β2-adrenergic receptor agonists, salbutamol binds to β2-adrenergic receptors with a higher affinity than β1-receptors. In the airways, activation of β2-receptors results in relaxation of bronchial smooth muscle. resulting in a widening of the airway (bronchodilation). Inhaled salbutamol sulfate has a rapid onset of action, providing relief within 5-15 minutes of administration.

In tocolysis, the activation of β2-receptors results in relaxation of uterine smooth muscle, thus delaying labour.

Adverse effects

Whilst salbutamol is well-tolerated, particularly when compared with previous therapies such as theophylline, like all medications there exists the potential for adverse drug reactions to occur - especially when in high doses, or when taken orally or intravenously.

Common adverse effects include: tremor, palpitations and headache. (Rossi, 2004)

Infrequent adverse effects include: tachycardia, muscle cramps, agitation, hypokalemia, hyperactivity in children, and insomnia. (Rossi, 2004)

Other brand names

Salbutamol is sold under the brand names Airomir, Asmol, Proventil, Sultanol, Ventolin and Volmax.

Read more at Wikipedia.org


[List your site here Free!]


Muro Pharmaceutical and Sanofi-Synthelabo Make Announcement
From Business Wire, 9/15/99

TEWKSBURY, Mass./NEW YORK--(BW Healthwire)--Sept. 15, 1999--

Muro Pharmaceutical, Inc. and Sanofi-Synthelabo Inc. today announced that Muro had acquired the marketing and distribution rights for Dynabac(R) (dirithromycin tablets) in the United States. Effective October 1, 1999, Muro Pharmaceutical, a subsidiary of ASTA Medica AG, Germany, will become the exclusive U.S. marketer of this significant macrolide antibiotic, which was recently granted supplementary FDA approval for the acute exacerbation of chronic bronchitis. Financial terms were not disclosed.

Dynabac(R) will immediately become a top priority for Muro's respiratory-focused sales force and managed care team. Muro will acquire Sanofi's entire existing Dynabac(R) inventory and will continue to purchase from Sanofi thereafter.

"Dynabac(R) is an excellent fit with our existing respiratory portfolio, so this is another major step forward in development of our American business," said Colin Stewart, President and Chief Executive Officer of Muro Pharmaceutical, Inc. "Top prescribers of macrolide antibiotics closely match those of our other products, including Volmax(R) (albuterol sulfate) extended-release tablets."

"Sanofi-Synthelabo is a world leader in the treatment of cardiovascular disease, thrombosis and sleep disorders," said Jeffrey P. Brennan, Vice President of Business Development for Sanofi-Synthelabo. "With the success in the U.S. of Avapro(R) and Plavix(R) and the imminent arrival of Ambien(R), we find it necessary to maintain a strong focus on these key therapeutic areas, which offer us the greatest opportunities for continued growth."

"Due to this focus," Mr. Brennan added, "the sales force of Sanofi-Synthelabo Inc. isn't configured to properly promote this product. We are pleased to sign this agreement with Muro. We believe its respiratory sales force will maximize the sales of Dynabac(R)."

Muro Pharmaceutical, Inc. is a United States subsidiary of ASTA Medica AG, a research based, international pharmaceutical company headquartered in Germany. ASTA Medica AG is a billion dollar a year company with leading products in the fields of anticancer drugs, central nervous system agents, and respiratory therapies. The ASTA Medica group is represented by thirty-five subsidiaries in more than thirty countries.

Sanofi-Synthelabo is among the world's top 20 pharmaceutical companies, with 33,000 employees in more than 100 countries and annual sales in excess of $6 billion. Headquarters are in Paris; U.S. headquarters are in New York City.

COPYRIGHT 1999 Business Wire
COPYRIGHT 2000 Gale Group

Return to Volmax
Home Contact Resources Exchange Links ebay